Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
March 06 2024 - 8:05AM
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset
clinical-stage biopharmaceutical company, focused on identifying
and developing treatments in high unmet need areas involving rare
diseases and multi-drug resistant (MDR) bacterial infections, today
announced that it will host a conference call and live audio
webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its
fourth quarter and full year financial results and provide an
update on its business and pipeline.
To access the call, please dial 1-877-704-4453
(domestic) or 1-201-389-0920 (international) and refer to
conference ID 13744458, or click on this Link and request a return
call. The audio webcast can be accessed on the "Events and
Presentations" page under the “Connect” tab of the Company's
website at www.sperotherapeutics.com. The archived
webcast will also be available on Spero's website for 30 days
following the call.
About Spero TherapeuticsSpero
Therapeutics, headquartered in Cambridge, Massachusetts, is a
multi-asset, clinical-stage biopharmaceutical company focused on
identifying, developing, novel therapies for rare diseases and
multi-drug resistant (MDR) bacterial infections with high unmet
need.
- Spero Therapeutics is developing
SPR720 as a novel oral therapy candidate for the treatment of a
rare, orphan pulmonary disease caused by non-tuberculous
mycobacterial infections.
- Tebipenem HBr is an investigational
drug in the United States being developed for the treatment of
complicated urinary tract infection (cUTI), including
pyelonephritis, caused by certain bacteria, in adult patients who
have limited treatment options; tebipenem HBr is not U.S. Food and
Drug Administration (FDA)-approved.
- Spero Therapeutics also has an
IV-administered next generation polymyxin product candidate,
SPR206, developed from its potentiator platform, which is in
development to treat MDR Gram-negative infections in the hospital
setting.
For more information, visit
https://sperotherapeutics.com.
Investor Relations Contact: Ted
JenkinsVice President, Investor Relations and Strategic
FinanceIR@sperotherapeutics.com (617) 798-4039
Media Inquiries: Lora Grassilli, Health Media
RelationsZeno Grouplora.grassilli@zenogroup.com646-932-3735
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Oct 2023 to Oct 2024